Actinium Pharmaceuticals, Inc. (delaware) · AMEX:ATNM
Actinium Pharmaceuticals, Inc. (delaware) — Actinium Pharmaceuticals — Investor Presentation (October 2026)
26 slides from Actinium Pharmaceuticals, Inc. (delaware)'s investor presentation, October 2026
Slide 1: Investor Presentation
Investor Presentation Pioneering Differentiated Radiotherapies for Patients with Unmet Needs October 2026 ATNM: NYSE AMERICAN
Slide 2: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor The information presented herein contains express and implied forward-looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Actinium Pharmaceuticals, Inc. (“Actinium”) that are not historical facts. These forward-looking stat
Slide 3: Investment Thesis: A Novel Biology-Driven Radiotherapy Pipeline
Investment Thesis: A Novel Biology-Driven Radiotherapy Pipeline Deep understanding of disease biology shapes a differentiated radiotherapy portfolio at an inflection point with several key 2026 readouts supported by cash runway into 2028 Two Solid Tumor Assets with Pan-Cancer Blockbuster Opportuniti
Slide 4: Radiopharma Landscape: A Strategic Void Awaits Differentiated Assets
Radiopharma Landscape: A Strategic Void Awaits Differentiated Assets Innovation Gap Innovative Pipeline 6 Big 3 Targets Pharma’s Dominate industry with an acquired pipeline (PSMA, radiotherapy SSTR2 & FAP) presence $17 Billion 300,000+ In high value M&A Sq. feet of on late-stage underutilized radio
Slide 5: Actinium is Well Positioned in the Current Radio Landscape
Actinium is Well Positioned in the Current Radio Landscape A Transformative Pipeline Across Three High Value Pillars Pillar Program Differentiation & Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 5
Slide 6: Innovation Focused R&D & Manufacturing Capabilities To Drive Value
Innovation Focused R&D & Manufacturing Capabilities To Drive Value Demonstrated ability to generate novel and highly differentiated radiotherapy programs as evidenced by our highly innovative pipeline Strong In-house R&D to be Complemented Demonstrated Leading-Edge Preclinical End-to-end Supply Chai
Slide 7: Solid Tumors: ATNM-400 & Actimab-A
Solid Tumors: ATNM-400 & Actimab-A February 18, 2022 ATNM-400: First-in-class, multi-indication Ac-225 targeted radiotherapy supported by robust preclinical data in mCRPC, NSCLC & Breast Cancer Actimab-A: Potential to synergize with PD-1 and other immune checkpoint inhibitors in solid tumors by depl
Slide 8: ATNM-400: Pan Cancer Radiotherapy Targeting 3 Blockbuster Indications
ATNM-400: Pan Cancer Radiotherapy Targeting 3 Blockbuster Indications Target implicated in disease biology & treatment resistance – NOT PSMA Pan-tumor potential: target expressed across multiple solid tumor indications Theranostic approach with Zr-89 for imaging and Ac-225 for therapy Prostate Cance
Slide 9: Blockbuster Market Opportunity for ATNM-400 in Prostate Cancer
Blockbuster Market Opportunity for ATNM-400 in Prostate Cancer Multiple near-term opportunities in non-responders and progressors with future expansion to earlier lines of treatment HSPC mHSPC mCRPC ATNM-400 Can Address Broad mCRPC Population ATNM-400 Potential Expansion in mHSPC 45 – 55K patients f
Slide 10: Transformative Therapeutic Potential of ATNM-400 for Prostate Cancer
Transformative Therapeutic Potential of ATNM-400 for Prostate Cancer Robust in vivo data show ATNM-400 achieves specific tumor uptake, decreased tumor cell proliferation, and superior efficacy versus 177Lu-PSMA-617, active agent in blockbuster radiotherapy Pluvicto® Specific Tumor Uptake & Robust Tr
Slide 11: Greater Efficacy and Synergy with ARPIs Supports Large Market
Greater Efficacy and Synergy with ARPIs Supports Large Market Mechanistic rationale & data supports potential of ATNM-400 in earlier line mCRPC as a monotherapy or ARPI combination ATNM-400 Monotherapy or in Combination with ARPI Enzalutamide/XTANDI is Superior to PSMA-Targeted Agents in Prostate Ca
Slide 12: ATNM-400 Could Address NSCLC Beyond Single-Mutation Therapies
ATNM-400 Could Address NSCLC Beyond Single-Mutation Therapies Compelling preclinical data for ATNM-400 in NSCLC supported by target biology, the mutation agnostic mechanism of Ac-225 and combination studies with external beam radiotherapy support backbone type of opportunity in the 2x larger than pr
Slide 13: Significant Market Expansion Opportunity Across EGFR-mutant NSCLC
Significant Market Expansion Opportunity Across EGFR-mutant NSCLC ATNM-400 outperformed 1st, 2nd & 3rd line approved therapies for EGFR-mutant NSCLC by 3-5x and had robust synergy in combination with 1st line osimertinib that is supported by clinical data with EBRT Osimertinib treatment increases AT
Slide 14: Compelling Efficacy Across All EGFR, KRAS-Mutant NSCLC Settings
Compelling Efficacy Across All EGFR, KRAS-Mutant NSCLC Settings Results Strongly Support ATNM-400’s Differentiated Profile in the Highly Competitive NSCLC Space and Potential Across 1st, 2nd & 3rd Line Settings, Alone or In Combination with Successful Therapies Competing for Market Share • AstraZene
Slide 15: Broad Potential Demonstrated Across Multiple Breast Cancer Settings
Broad Potential Demonstrated Across Multiple Breast Cancer Settings ATNM-400’s target antigen is overexpressed in breast cancer including tumors resistant to endocrine therapies such as tamoxifen and HER2 targeted therapies like Herceptin® as well as in TNBC HER2 Therapy Resistance Increases Surviva
Slide 16: Actimab-A: Tap Into the Blockbuster PD-1 Market By Depleting MDSCs
Actimab-A: Tap Into the Blockbuster PD-1 Market By Depleting MDSCs Actimab-A can be synergistic with PD-1 inhibitors by depleting MDSCs, an immune cell subtype implicated in poor response and outcomes to PD-1 inhibitors, potentially opening and expanding a $40+ billion market Clinical Data Shows Hig
Slide 17: Actimab-A MDSC + PD-1 Combination Trials: GBM and Basket
Actimab-A MDSC + PD-1 Combination Trials: GBM and Basket Trials supported by compelling preclinical data and mechanistic synergy will enroll patients across 4 tumor types Actimab-A targeting of MDSCs rescues Actimab-A is cytotoxic to Actimab-A homes to tumor-resident MDSCs T cell response ex vivo1 p
Slide 18: Hematology Portfolio: AML Therapeutics & Targeted Conditioning
Hematology Portfolio: AML Therapeutics & Targeted Conditioning February 18, 2022 Actimab-A: Phase 2/3 ready, mutation agnostic Ac-225 AML therapy Iomab-B: Phase 2/3 ready BMT targeted conditioning agent Iomab-ACT: Potential universal conditioning to improve access and outcomes for cell & gene therap
Slide 19: Heme Assets - Potential to Transform the AML & MDS Treatment Journey
Heme Assets - Potential to Transform the AML & MDS Treatment Journey Late-stage differentiated radio assets have strong synergy with favorable commercial dynamics and can address the unmet needs of 110,000 patients in the U.S. and EU Iomab-B BMT Conditioning: R/R AML Phase 2/3 Therapy BMT Post-BMT I
Slide 20: Actimab-A: Universal AML Backbone, De-Risked and Partner-Ready
Actimab-A: Universal AML Backbone, De-Risked and Partner-Ready Only CD33 targeting clinical stage radiotherapy supported by strong data and Actimab-A NCI CRADA Actimab-A: AML & MDS Therapeutics • Mutation agnostic Ac-225 backbone therapy with strong data in high-risk patients • Aligned with the FDA
Slide 21: Actimab-A + CLAG-M: Results Support Phase 2/3 Trial in R/R AML
Actimab-A + CLAG-M: Results Support Phase 2/3 Trial in R/R AML High Rates of MRD Negativity and Improved Phase 2/3 Trial to Enroll Patients with 1st or 2nd Salvage Survival Outcomes in High-Risk R/R Patients1 R/R AML, Group Had Best Outcomes in Phase 1b Trial • 24-month median overall survival in th
Slide 22: Iomab-B/ACT: Targeted Conditioning to Unlock BMT, Cell & Gene Therapy
Iomab-B/ACT: Targeted Conditioning to Unlock BMT, Cell & Gene Therapy Only CD45-targeted conditioning radiotherapy in development — de-risked by SIERRA and 500+ patients treated Iomab-B and Iomab-ACT: Targeted Conditioning, A Gateway to Curative Therapies • Two CD45 targeted radiotherapies designed
Slide 23: Iomab-ACT Further Expands Heme Portfolio Market Opportunity
Iomab-ACT Further Expands Heme Portfolio Market Opportunity BMT & Gene Therapy Conditioning – Commercial CAR-T Phase 1B/2 Trial Sickle Cell Disease BMT Phase 1 Trial Enrollment Enrollment N = 30 patients N = 24 patients (single arm) PRIMARY SECONDARY PRIMARY & SECONDARY OBJECTIVES OBJECTIVES OBJECTI
Slide 24: 2026-2027 Outlook & Milestones
2026-2027 Outlook & Milestones February 18, 2022 Transformational period with multiple first-in-class therapies reaching inflection points supporting our vision to be a leading fully-integrated targeted radiotherapy company ATNM: NYSE AMERICAN
Slide 25: 2026-2027: A Period of Transformational Milestones and Data Readouts
2026-2027: A Period of Transformational Milestones and Data Readouts 4Q:26 Target disclosure at a medical conference 4Q:26 Demonstration of pan cancer potential 4Q:26 Host KOL webinar ATNM-400 4Q:26 Initial biodistribution and safety data in prostate cancer 2027 Translational data in additional indi
Slide 26: Thank You
Thank You Actinium Pharmaceuticals, Inc. ATNM: NYSE AMERICAN
Actinium Pharmaceuticals — Investor Presentation (October 2026) on 6ix